108 related articles for article (PubMed ID: 21918510)
1. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
Simon T; Steg PG; Becquemont L; Verstuyft C; Kotti S; Schiele F; Ferrari E; Drouet E; Grollier G; Danchin N
Clin Pharmacol Ther; 2011 Oct; 90(4):561-7. PubMed ID: 21918510
[TBL] [Abstract][Full Text] [Related]
2. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.
Paré G; Ross S; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Fox KA; Eikelboom JW
Circ Cardiovasc Genet; 2012 Apr; 5(2):250-6. PubMed ID: 22368149
[TBL] [Abstract][Full Text] [Related]
3. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
5. [Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction].
Guxens M; Tomás M; Elosua R; Aldasoro E; Segura A; Fiol M; Sala J; Vila J; Fullana M; Sentí M; Vega G; de la Rica M; Marrugat J;
Rev Esp Cardiol; 2008 Mar; 61(3):269-75. PubMed ID: 18361900
[TBL] [Abstract][Full Text] [Related]
6. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE).
Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL;
Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
[TBL] [Abstract][Full Text] [Related]
8. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice.
Zeymer U; Gitt AK; Jünger C; Heer T; Wienbergen H; Koeth O; Bauer T; Mark B; Zahn R; Gottwik M; Senges J;
Eur Heart J; 2006 Nov; 27(22):2661-6. PubMed ID: 17043060
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.
Ho PM; Fihn SD; Wang L; Bryson CL; Lowy E; Maynard C; Magid DJ; Peterson ED; Jesse RL; Rumsfeld JS
Am Heart J; 2007 Nov; 154(5):846-51. PubMed ID: 17967588
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
Mangiacapra F; Muller O; Ntalianis A; Trana C; Heyndrickx GR; Bartunek J; Vanderheyden M; Wijns W; De Bruyne B; Barbato E
Am J Cardiol; 2010 Nov; 106(9):1208-11. PubMed ID: 21029814
[TBL] [Abstract][Full Text] [Related]
11. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study.
Bonde L; Sorensen R; Fosbøl EL; Abildstrøm SZ; Hansen PR; Kober L; Schramm TK; Bretler DM; Weeke P; Olesen J; Torp-Pedersen C; Gislason GH
J Am Coll Cardiol; 2010 Mar; 55(13):1300-7. PubMed ID: 20338489
[TBL] [Abstract][Full Text] [Related]
12. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.
Wiederkehr D; Ogbonnaya A; Casciano R; Makenbaeva D; Mozaffari E; Corbelli J
Curr Med Res Opin; 2009 Sep; 25(9):2327-34. PubMed ID: 19635046
[TBL] [Abstract][Full Text] [Related]
14. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
Banerjee S; Weideman RA; Weideman MW; Little BB; Kelly KC; Gunter JT; Tortorice KL; Shank M; Cryer B; Reilly RF; Rao SV; Kastrati A; de Lemos JA; Brilakis ES; Bhatt DL
Am J Cardiol; 2011 Mar; 107(6):871-8. PubMed ID: 21247527
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction.
Morray B; Goldenberg I; Moss AJ; Zareba W; Ryan D; McNitt S; Eberly SW; Glazko G; Mathew J
Am J Cardiol; 2007 Apr; 99(8):1100-5. PubMed ID: 17437735
[TBL] [Abstract][Full Text] [Related]
16. Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry).
Caggegi A; Capodanno D; Capranzano P; Chisari A; Ministeri M; Mangiameli A; Ronsivalle G; Ricca G; Barrano G; Monaco S; Di Salvo ME; Tamburino C
Am J Cardiol; 2011 Aug; 108(3):355-9. PubMed ID: 21545992
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
18. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
Mega JL; Close SL; Wiviott SD; Man M; Duvvuru S; Walker JR; Sundseth SS; Collet JP; Delaney JT; Hulot JS; Murphy SA; Paré G; Price MJ; Sibbing D; Simon T; Trenk D; Antman EM; Sabatine MS
J Thromb Thrombolysis; 2016 Apr; 41(3):374-83. PubMed ID: 26573179
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
